Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
Natalia Navas Jesús Hermosilla Anabel Torrente-L(o)pez Jos(e) Hern(a)ndez-Jim(e)nez Jose Cabeza Raquel P(e)rez-Robles Antonio Salmer(o)n-García
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
摘要
关键词
COVID-19/Tocilizumab/Critical quality attributes/IV and SC medicinesKey words
COVID-19/Tocilizumab/Critical quality attributes/IV and SC medicines引用本文复制引用
Natalia Navas,Jesús Hermosilla,Anabel Torrente-L(o)pez,Jos(e) Hern(a)ndez-Jim(e)nez,Jose Cabeza,Raquel P(e)rez-Robles,Antonio Salmer(o)n-García..Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes[J].药物分析学报（英文）,2020,10(6):532-545,14.基金项目
This study was partially funded by Project FIS: PI-17/00547 (Instituto Carlos III, Ministerio de Economía y Competitividad, Spain), which means that it was also partially supported by Euro-pean Regional Development Funds (ERDF). Anabel Torrente-L(o)pez is currently granted a FPU predoctoral grant of reference FPU18/03131 from the Ministry of Universities, Spain. The authors would like to thank the University of Granada (Spain) for the support and for enabling us to use the laboratories at the Department of Analytical Chemistry in the Science Faculty during the hard days of lockdown in Spain. （Instituto Carlos III, Ministerio de Economía y Competitividad, Spain）
